Shaila Misri1, Elena Swift2, Jasmin Abizadeh2, Radhika Shankar2. 1. Reproductive Mental Health Program, BC Women's Hospital, Mental Health Building, P1-228, 4500 Oak Street, Vancouver, British Columbia, Canada V6H 3N1. 2. Reproductive Mental Health Program, BC Children's & Women's Hospital, Vancouver, BC, Canada.
Abstract
OBJECTIVES: Antidepressants are the first line treatment for moderate to severe major depressive disorder (MDD) in perinatal and general populations. However, there appears to be paucity of evidence around antidepressant use in women with postpartum depression or anxiety. Selection of an appropriate antidepressant is crucial in promoting efficacy, optimizing tolerability, and managing comorbid anxiety or depression. Our aim was to investigate the treatment effect and tolerability profile of desvenlafaxine, and to examine the functionality of women with postpartum depression or anxiety after desvenlafaxine treatment. METHODS:Fifteen postpartum women with depression or anxiety completed this 12-week prospective pilot study with a flexible dose of desvenlafaxine (50-100 mg). Participants were recruited at a tertiary care level program. Measures of depression (Montgomery-Åsberg Depression Rating Scale, MADRS), anxiety (Hamilton Anxiety Rating Scale, HAM-A), worry (Penn State Worry Questionnaire, PSWQ) and functional impairment (Sheehan Disability Scale, SDS) were completed at baseline, 8 weeks, and 12 weeks. RESULTS: In the intention-to-treat analysis (n = 17), the majority of women responded to medication (88.2%, n = 15), and reached remission of depressive (82.4%, n = 14) and anxiety symptoms (82.4%, n = 14). Remission of depression was achieved in a mean of 6.9 weeks [standard deviation (SD) = 3.01] at a mean dose of 71 mg/day (SD = 25.7). Significant decreases were observed on PSWQ worry scores (p < 0.0001) and SDS scores for social (p < 0.0001) and family life impairment (p < 0.0001). The medication was generally well tolerated. CONCLUSION: The results of our prospective pilot study suggest that treatment with desvenlafaxine of postpartum mothers with depression or anxiety can lead to symptom remission and restoration of functionality.
RCT Entities:
OBJECTIVES: Antidepressants are the first line treatment for moderate to severe major depressive disorder (MDD) in perinatal and general populations. However, there appears to be paucity of evidence around antidepressant use in women with postpartum depression or anxiety. Selection of an appropriate antidepressant is crucial in promoting efficacy, optimizing tolerability, and managing comorbid anxiety or depression. Our aim was to investigate the treatment effect and tolerability profile of desvenlafaxine, and to examine the functionality of women with postpartum depression or anxiety after desvenlafaxine treatment. METHODS: Fifteen postpartum women with depression or anxiety completed this 12-week prospective pilot study with a flexible dose of desvenlafaxine (50-100 mg). Participants were recruited at a tertiary care level program. Measures of depression (Montgomery-Åsberg Depression Rating Scale, MADRS), anxiety (Hamilton Anxiety Rating Scale, HAM-A), worry (Penn State Worry Questionnaire, PSWQ) and functional impairment (Sheehan Disability Scale, SDS) were completed at baseline, 8 weeks, and 12 weeks. RESULTS: In the intention-to-treat analysis (n = 17), the majority of women responded to medication (88.2%, n = 15), and reached remission of depressive (82.4%, n = 14) and anxiety symptoms (82.4%, n = 14). Remission of depression was achieved in a mean of 6.9 weeks [standard deviation (SD) = 3.01] at a mean dose of 71 mg/day (SD = 25.7). Significant decreases were observed on PSWQ worry scores (p < 0.0001) and SDS scores for social (p < 0.0001) and family life impairment (p < 0.0001). The medication was generally well tolerated. CONCLUSION: The results of our prospective pilot study suggest that treatment with desvenlafaxine of postpartum mothers with depression or anxiety can lead to symptom remission and restoration of functionality.
Authors: Michael E Thase; Susan G Kornstein; Jean-Michel Germain; Qin Jiang; Christine Guico-Pabia; Philip T Ninan Journal: CNS Spectr Date: 2009-03 Impact factor: 3.790
Authors: Kimberly A Yonkers; Haiqun Lin; Heather B Howell; A Christopher Heath; Lee S Cohen Journal: J Clin Psychiatry Date: 2008-04 Impact factor: 4.384
Authors: Raymond W Lam; Sidney H Kennedy; Sophie Grigoriadis; Roger S McIntyre; Roumen Milev; Rajamannar Ramasubbu; Sagar V Parikh; Scott B Patten; Arun V Ravindran Journal: J Affect Disord Date: 2009-08-11 Impact factor: 4.839
Authors: Anita H Clayton; Susan G Kornstein; Boadie W Dunlop; Kristen Focht; Jeff Musgnung; Tanya Ramey; Weihang Bao; Philip T Ninan Journal: J Clin Psychiatry Date: 2013-10 Impact factor: 4.384
Authors: Stephen J Kanes; Helen Colquhoun; James Doherty; Shane Raines; Ethan Hoffmann; David R Rubinow; Samantha Meltzer-Brody Journal: Hum Psychopharmacol Date: 2017-03 Impact factor: 1.672